SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Juventas Therapeutics, Inc. Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure; Looks to Raise $25 Million in Series B